amifostine anhydrous has been researched along with Radiodermatitis in 13 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
Radiodermatitis: A cutaneous inflammatory reaction occurring as a result of exposure to ionizing radiation.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We evaluated the toxicity and efficacy of a Hypofractionated and intensively Accelerated RT regimen supported with amifostine Cytoprotection (HypoARC) in a cohort of 72 high-risk breast cancer patients treated with modified mastectomy or conservative surgery and FEC (5-fluorouracil/epirubicin/cyclophosphamide) chemotherapy." | 3.71 | Hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC): a short, safe, and effective postoperative regimen for high-risk breast cancer patients. ( Frangiadaki, C; Georgoulias, V; Giatromanolaki, A; Kakolyris, S; Koukourakis, MI; Kouroussis, C; Retalis, G; Sivridis, E, 2002) |
| "Nearly two thirds of all patients with cancer receive radiation therapy during the course of treatment, frequently resulting in acute skin and mucosal toxicities." | 2.49 | Prevention and management of radiation-induced dermatitis, mucositis, and xerostomia. ( Pace, MB; Radvansky, LJ; Siddiqui, A, 2013) |
| "radiotherapy plus amifostine for cancer treatment." | 2.43 | Amifostine reduces side effects and improves complete response rate during radiotherapy: results of a meta-analysis. ( Clark, LG; Clark, OA; Sasse, AD; Sasse, EC, 2006) |
| "Radiodermatitis and radioinduced oral mucositis are frequent and significant side effects among patients with breast and head and neck cancer, respectively." | 1.51 | Preventing Radiation-Induced Injury by Topical Application of an Amifostine Metabolite-Loaded Thermogel. ( Benel, L; Bloy, C; Bricout, D; Chargari, C; Clémenson, C; Deutsch, E; Haddad, R; Liu, W; Mondini, M; Soyez-Herkert, L; Wang-Zhang, X, 2019) |
| "Xerostomia has been seen in 15 patients (Grade I) and 5 patients (Grade II) after administration of amifostine." | 1.30 | Amifostine--a radioprotector in locally advanced head and neck tumors. ( Prott, FJ; Schönekäs, KG; Wagner, W, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (15.38) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 4 (30.77) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Koukourakis, IM | 1 |
| Panteliadou, M | 2 |
| Giakzidis, AG | 1 |
| Nanos, C | 1 |
| Abatzoglou, I | 1 |
| Giatromanolaki, A | 4 |
| Koukourakis, MI | 5 |
| Clémenson, C | 1 |
| Liu, W | 1 |
| Bricout, D | 1 |
| Soyez-Herkert, L | 1 |
| Chargari, C | 1 |
| Mondini, M | 1 |
| Haddad, R | 1 |
| Wang-Zhang, X | 1 |
| Benel, L | 1 |
| Bloy, C | 1 |
| Deutsch, E | 1 |
| Radvansky, LJ | 1 |
| Pace, MB | 1 |
| Siddiqui, A | 1 |
| Tsoutsou, PG | 2 |
| Abatzoglou, IM | 2 |
| Sismanidou, K | 2 |
| Sivridis, E | 3 |
| Karpouzis, A | 1 |
| Tsiarkatsi, M | 1 |
| Karapantzos, I | 1 |
| Daniilidis, V | 1 |
| Kouskoukis, C | 1 |
| Kouloulias, VE | 1 |
| Kouvaris, JR | 1 |
| Kokakis, JD | 1 |
| Kostakopoulos, A | 1 |
| Mallas, E | 1 |
| Metafa, A | 1 |
| Vlahos, LJ | 1 |
| Sasse, AD | 1 |
| Clark, LG | 1 |
| Sasse, EC | 1 |
| Clark, OA | 1 |
| Vygodskaia, AL | 1 |
| Vinskaia, NP | 1 |
| Krimker, VM | 1 |
| Peters, K | 1 |
| Mücke, R | 1 |
| Hamann, D | 1 |
| Ziegler, PG | 1 |
| Fietkau, R | 1 |
| Schönekäs, KG | 1 |
| Wagner, W | 1 |
| Prott, FJ | 1 |
| Kouroussis, C | 1 |
| Kakolyris, S | 1 |
| Frangiadaki, C | 1 |
| Retalis, G | 1 |
| Georgoulias, V | 1 |
| Ivanov, EV | 1 |
| Ponomareva, TV | 1 |
| Merkushev, GN | 1 |
| Pil'shchik, EM | 1 |
| Livshits, RE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Single Center, Open Label Clinical Investigation on the Treatment of Radiation Induced Dermatitis With Radiation Care® Gel[NCT04995328] | 23 participants (Actual) | Interventional | 2021-08-03 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for amifostine anhydrous and Radiodermatitis
| Article | Year |
|---|---|
Prevention and management of radiation-induced dermatitis, mucositis, and xerostomia.
Topics: Administration, Topical; Amifostine; Analgesics; Antineoplastic Protocols; Combined Modality Therapy | 2013 |
Amifostine reduces side effects and improves complete response rate during radiotherapy: results of a meta-analysis.
Topics: Amifostine; Cystitis; Deglutition Disorders; Esophagitis; Humans; Neoplasms; Radiation Injuries; Rad | 2006 |
[Radioprotectors of the skin].
Topics: Amifostine; Animals; beta-Aminoethyl Isothiourea; Cysteamine; Dimethyl Sulfoxide; Drug Combinations; | 1978 |
2 trials available for amifostine anhydrous and Radiodermatitis
| Article | Year |
|---|---|
Radiochemotherapy with cetuximab, cisplatin, and amifostine for locally advanced head and neck cancer: a feasibility study.
Topics: Adult; Aged; Aged, 80 and over; Amifostine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2010 |
Supportive use of amifostine in patients with head and neck tumors undergoing radio-chemotherapy. Is it possible to limit the duration of the application of amifostine?
Topics: Adolescent; Adult; Aged; Amifostine; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; C | 1999 |
8 other studies available for amifostine anhydrous and Radiodermatitis
| Article | Year |
|---|---|
Long-Term Results of Postoperative Hypofractionated Accelerated Breast and Lymph Node Radiotherapy (HypoAR) with Hypofractionated Boost.
Topics: Amifostine; Female; Humans; Lymph Nodes; Mastectomy, Segmental; Radiation Dose Hypofractionation; Ra | 2021 |
Preventing Radiation-Induced Injury by Topical Application of an Amifostine Metabolite-Loaded Thermogel.
Topics: Amifostine; Animals; Blood Pressure; Breast Neoplasms; Disease Models, Animal; DNA Damage; Dogs; Dru | 2019 |
Hypofractionated and accelerated radiotherapy with subcutaneous amifostine cytoprotection as short adjuvant regimen after breast-conserving surgery: interim report.
Topics: Adult; Aged; Amifostine; Breast Diseases; Breast Neoplasms; Female; Humans; Mastectomy, Segmental; M | 2009 |
Postmastectomy hypofractionated and accelerated radiation therapy with (and without) subcutaneous amifostine cytoprotection.
Topics: Adult; Aged; Aged, 80 and over; Amifostine; Breast Neoplasms; Case-Control Studies; Combined Modalit | 2013 |
Impact on cytoprotective efficacy of intermediate interval between amifostine administration and radiotherapy: a retrospective analysis.
Topics: Amifostine; Female; Humans; Injections, Intravenous; Male; Middle Aged; Mucous Membrane; Neoplasms; | 2004 |
[Quantitative evaluation of the effectiveness of radiomodifiers in local irradiation of the skin].
Topics: Amifostine; Animals; Female; Metronidazole; Mice; Radiation-Protective Agents; Radiation-Sensitizing | 1982 |
Amifostine--a radioprotector in locally advanced head and neck tumors.
Topics: Adult; Aged; Amifostine; Deglutition Disorders; Female; Head and Neck Neoplasms; Humans; Male; Middl | 1999 |
Hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC): a short, safe, and effective postoperative regimen for high-risk breast cancer patients.
Topics: Adult; Aged; Alkaline Phosphatase; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Breas | 2002 |